MGMT and glioblastoma: CeTeG/NOA-09 screened >650 patients to enrol 141 patients aged 18 to 70 with MGMT-methylated GBM and randomly assigned them to a combined lomustine/temozolomide regimen during and after radiation therapy (up to six 42-day cycles of lomustine 100 mg/m2 on day 1 and temozolomide 100 mg/m2 on days 2 to 6) or standard therapy (17).